EUVIMEDEUVIMED entdecken
LeserbriefFallbericht

Novel JAK‐1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: A case report

Mingwei Ma, Siyi Lu, Xiujuan Hou iD, Chen Li iD

International Journal of Rheumatic Diseases · 2023-11 · 26 (11) · 2335-2337

DOI: 10.1111/1756-185x.14774 ↗

Kurz gefasst

Leserbrief in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 07.06.2023. Verfasst von Mingwei Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Ch…. Hauptthemen laut MEDLINE: Acquired Hyperostosis Syndrome, Janus Kinase Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 8 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acquired Hyperostosis SyndromeJanus Kinase InhibitorsHumansHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

SAPHO syndromeautoinflammatory diseasetreatment optionupadacitinib

Substanzen

upadacitinibHeterocyclic Compounds, 3-RingJanus Kinase Inhibitors

Autor:innen und Institutionen

  • School of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Rheumatology, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, China.
  • Department of Rheumatology, Fangshan Hospital Beijing University of Chinese Medicine, Beijing, China.

ORCID-Profile: Xiujuan Hou, Chen Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ma, M., Lu, S., Hou, X., & Li, C. (2023). Novel JAK‐1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: A case report. International Journal of Rheumatic Diseases, 26(11), 2335-2337. https://doi.org/10.1111/1756-185x.14774

Vancouver

Ma M, Lu S, Hou X, Li C. Novel JAK‐1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: A case report. International Journal of Rheumatic Diseases. 2023;26(11):2335-2337. doi:10.1111/1756-185x.14774

BibTeX
@article{Ma2023,
  author = {Ma, Mingwei and Lu, Siyi and Hou, Xiujuan and Li, Chen},
  title = {Novel JAK‐1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: A case report},
  journal = {International Journal of Rheumatic Diseases},
  year = {2023},
  volume = {26},
  number = {11},
  pages = {2335--2337},
  doi = {10.1111/1756-185x.14774}
}
Kostenlos starten →